

1 **Appendix 1. Strategy Use and Association with HCV Treatment Over Time**

Cluster and Strategy	FY15	FY16	FY17	FY18	FY19	Most Popular	Timing	Dose	Diffusion	Core Strategy
	n=80	n=105	n=109	n=88	n=58	P	Δ	E	D	H,L
<b>Infrastructure</b>										
• Change physical structure and equipment	53%	51%	54%	57%	29%	P			D	L
• Change the record systems	71%	57%	52%	40%	31%	P	Δ			H
• Change the location of clinical service sites	26%	37%	39%	34%	14%					
• Develop a separate organization or group responsible for disseminating HCV care	23%	33%	19%	13%	7%		Δ			
• Mandate changes to HCV care	55%	52%	35%	27%	22%		Δ		D	
• Create or change credentialing and/or licensure standards	29%	30%	17%	16%	17%		Δ			
• Participate in liability reform efforts that make clinicians more willing to deliver the clinical innovation	4%	11%	10%	8%	5%					
• Change accreditation or membership requirements	4%	1%	2%	0%	0%					
<b>Financial</b>										
• Access new funding	30%	41%	41%	47%	21%					H
• Alter incentive/allowance structures	5%	10%	9%	5%	5%				D	L
• Provide financial disincentives for failure to implement or use the clinical innovations	0%	2%	0%	1%	2%					
• Respond to proposals to deliver HCV care	44%	51%	34%	34%	17%		Δ			
• Change billing	11%	14%	10%	5%	5%					
• Place HCV medications on the formulary	70%	69%	61%	45%	28%	P	Δ		D	
• Alter patient fees	0%	0%	0%	0%	0%					

• Use capitated payments	0%	1%	1%	0%	0%					
• Use other payment schemes	<b>5%</b>	2%	4%	0%	0%				E	
<b>Support clinicians</b>										
• Create new clinical teams	<b>46%</b>	<b>50%</b>	39%	36%	21%				E	D L
• Facilitate the relay of clinical data to providers	<b>56%</b>	<b>68%</b>	70%	56%	41%	P				
• Revise professional roles	<b>50%</b>	<b>55%</b>	39%	27%	29%		Δ			D L
• Develop reminder systems for clinicians	34%	44%	34%	43%	29%					D
• Develop resource sharing agreements	<b>26%</b>	35%	28%	25%	21%					H
<b>Provide interactive assistance</b>										
• Use outside assistance often called “facilitation”	8%	12%	24%	20%	12%		Δ			
• Provide technical assistance	<b>15%</b>	25%	25%	<b>19%</b>	12%					D L
• Provide clinical supervision	<b>44%</b>	<b>48%</b>	35%	32%	28%					D L
• Use a centralized system to deliver facilitation	<b>28%</b>	28%	25%	<b>24%</b>	24%				E	H
<b>Adapt and tailor to the context</b>										
• Use data experts to manage HCV data	<b>58%</b>	<b>70%</b>	69%	<b>44%</b>	47%	P	Δ		E	H
• Use data warehousing techniques	<b>85%</b>	91%	92%	86%	<b>81%</b>	P				D L
• Tailor strategies to deliver HCV care	<b>63%</b>	81%	73%	70%	69%	P	Δ			D H,L
• Promote adaptability	<b>55%</b>	75%	70%	61%	52%	P	Δ			H
<b>Train and educate stakeholders</b>										
• Conduct educational meetings	<b>51%</b>	64%	68%	53%	<b>41%</b>	P				
• Have an expert in HCV care meet with providers to educate them	<b>41%</b>	53%	51%	48%	33%					
• Provide ongoing HCV training	<b>49%</b>	60%	54%	<b>44%</b>	34%				E	
• Facilitate the formation of groups of providers and fostered a collaborative learning environment	<b>44%</b>	<b>43%</b>	<b>38%</b>	31%	26%					
• Developed formal educational materials	39%	35%	39%	30%	12%					

• Distribute educational materials	55%	<b>55%</b>	58%	52%	33%				
• Provide ongoing consultation with one or more HCV treatment experts	58%	71%	59%	56%	55%	P			
• Train designated clinicians to train others	20%	26%	26%	20%	17%			D	
• Vary the information delivery methods to cater to different learning styles when presenting new information	<b>36%</b>	36%	31%	32%	26%				
• Give providers opportunities to shadow other experts in HCV	33%	22%	<b>20%</b>	<b>23%</b>	19%				
• Use educational institutions to train clinicians	<b>11%</b>	<b>15%</b>	12%	19%	14%			E	
<b><i>Develop stakeholder interrelationships</i></b>									
• Build a local coalition/team to address challenges	<b>53%</b>	<b>53%</b>	<b>38%</b>	27%	26%	Δ		D	L
• Conduct local consensus discussions	<b>48%</b>	<b>54%</b>	<b>50%</b>	32%	22%	Δ			
• Obtain formal written commitments from key partners that state what they will do to implement HCV care	4%	4%	6%	7%	0%			E	
• Recruit, designate, and/or train leaders	<b>26%</b>	<b>23%</b>	18%	14%	10%				
• Inform local opinion leaders about advances in HCV care	<b>49%</b>	46%	<b>40%</b>	<b>32%</b>	29%			E	
• Share the knowledge gained from quality improvement efforts with other sites outside your medical center	<b>38%</b>	57%	<b>54%</b>	36%	31%	Δ	E		H
• Identify and prepare champions	<b>50%</b>	52%	<b>50%</b>	40%	38%			D	L
• Organize support teams of clinicians, give them time to share the lessons learned and support	26%	<b>32%</b>	32%	<b>18%</b>	17%				

one another's learning							
• Use advisory boards and interdisciplinary workgroups to provide input into HCV policies and elicit recommendations	26%	22%	21%	14%	10%		
• Seek the guidance of experts in implementation	44%	50%	44%	35%	33%		
• Build on existing high-quality working relationships and networks to promote information sharing and problem solving	<b>61%</b>	71%	62%	58%	47%	P	
• Use modeling or simulated change	<b>13%</b>	<b>15%</b>	11%	10%	5%		
• Partner with a university to share ideas	<b>14%</b>	11%	13%	17%	7%		E
• Make efforts to identify early adopters to learn from their experiences	<b>16%</b>	<b>24%</b>	<b>21%</b>	<b>15%</b>	12%		E
• Visit other sites outside your medical center to try to learn from their experiences	<b>15%</b>	20%	18%	18%	16%		
• Develop an implementation glossary	3%	6%	6%	5%	2%		
• Involve executive boards	23%	<b>33%</b>	29%	17%	14%		
<b><i>Use evaluative and iterative strategies</i></b>							
• Assess for readiness and identify barriers and facilitators to change	26%	<b>30%</b>	26%	22%	17%		
• Conduct a local needs assessment	45%	43%	39%	24%	24%	Δ	H
• Develop a formal implementation blueprint	34%	<b>36%</b>	29%	22%	14%		H
• Start with small pilot studies and then scale them up	23%	25%	23%	17%	10%		D H
• Collect and summarize clinical performance data and give it to clinicians and	<b>21%</b>	<b>26%</b>	30%	19%	19%		

administrators to implement changes in a cyclical fashion using small tests of change before making system-wide changes

• Conduct small tests of change, measured outcomes, and then refine these tests	19%	<b>21%</b>	<b>27%</b>	18%	10%				D	L
• Develop and use tools for quality monitoring	41%	32%	28%	22%	16%		Δ		D	
• Develop and organize systems that monitor clinical processes and/or outcomes for the purpose of quality assurance and improvement	30%	<b>28%</b>	24%	13%	12%		Δ			
• Intentionally examine the efforts to promote HCV care	61%	<b>69%</b>	61%	52%	43%				P	
• Develop strategies to obtain and use patient and family feedback	20%	<b>20%</b>	11%	13%	10%					
<b>Engage consumers</b>										
• Involve patients/consumers and family members	50%	61%	50%	44%	34%					
• Engage in efforts to prepare patients to be active participants in HCV care	<b>63%</b>	57%	50%	43%	34%		P	Δ	D	L
• Intervene with patients/consumers to promote uptake and adherence to HCV treatment	71%	79%	68%	60%	50%		P	Δ		
• Use mass media to reach large numbers of people	18%	36%	56%	34%	12%			Δ		
• Promote demand for HCV care among patients through any other means	<b>40%</b>	52%	59%	<b>42%</b>	31%			Δ		

1 **Bold italicized** denotes  $p < .05$  for association between strategy and HCV treatment volume (rho

2 range=.19-.41)

3 P = Most popular strategies across active implementation years (n=14)

4 Δ = Strategy use changed over time (n=21)

5 E = Strategy has dose effect on HCV treatment volume (n=11)

6 D = Strategy differed in use by Treatment Diffusion group in at least one of the four implementation years

7 (n=18)

1 H = Core HIT Strategies (n=11)  
2 L = Local Core Strategies (n=11)

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

1 **Appendix 2. Implementation Strategies Associated with Treatment Diffusion in**  
 2 **Specific Patterns**

<b>Strategy</b>	<b>FY15</b>	<b>FY16</b>	<b>FY17</b>	<b>FY18</b>	<b>FY19</b>
Change physical structure and equipment					
<i>Innovator</i>	63%	26%	39%	<b>71%</b>	7%
<i>Majority</i>	48%	<b>64%</b>	53%	50%	38%
<i>Laggard</i>	55%	38%	<b>81%</b>	60%	36%
Mandate changes to HCV care					
<i>Innovator</i>	<b>53%</b>	52%	35%	38%	0%
<i>Majority</i>	<b>58%</b>	53%	31%	25%	28%
<i>Laggard</i>	45%	<b>50%</b>	50%	20%	36%
Alter incentive/allowance structures					
<i>Innovator</i>	<b>16%</b>	9%	9%	0%	0%
<i>Majority</i>	0%	8%	<b>10%</b>	8%	9%
<i>Laggard</i>	9%	<b>19%</b>	6%	0%	0%
Place HCV medications on the formulary					
<i>Innovator</i>	68%	<b>83%</b>	61%	43%	7%
<i>Majority</i>	<b>64%</b>	64%	64%	44%	28%
<i>Laggard</i>	<b>100%</b>	69%	50%	53%	55%
Create new clinical teams					
<i>Innovator</i>	58%	<b>61%</b>	57%	33%	7%
<i>Majority</i>	<b>44%</b>	47%	30%	38%	28%
<i>Laggard</i>	36%	44%	<b>56%</b>	33%	18%
Revise professional roles					
<i>Innovator</i>	<b>68%</b>	57%	26%	14%	7%
<i>Majority</i>	44%	<b>55%</b>	36%	35%	34%
<i>Laggard</i>	45%	56%	<b>69%</b>	20%	45%
Develop reminder systems for clinicians					
<i>Innovator</i>	21%	30%	39%	<b>43%</b>	13%
<i>Majority</i>	32%	<b>48%</b>	33%	44%	44%
<i>Laggard</i>	<b>64%</b>	44%	31%	40%	9%
Have someone from inside the clinic tasked with “local technical assistance”					
<i>Innovator</i>	<b>26%</b>	13%	26%	14%	13%
<i>Majority</i>	14%	<b>30%</b>	19%	25%	16%
<i>Laggard</i>	0%	19%	<b>50%</b>	7%	0%
Provide clinical supervision					
<i>Innovator</i>	<b>47%</b>	30%	39%	14%	20%
<i>Majority</i>	44%	<b>53%</b>	36%	42%	34%
<i>Laggard</i>	36%	<b>50%</b>	25%	20%	18%
Use data warehousing techniques					
<i>Innovator</i>	<b>89%</b>	78%	87%	86%	80%
<i>Majority</i>	84%	<b>95%</b>	93%	88%	81%

<i>Laggard</i>	82%	94%	<b>94%</b>	80%	82%
Tailor strategies to deliver HCV care					
<i>Innovator</i>	68%	74%	<b>87%</b>	81%	53%
<i>Majority</i>	56%	<b>86%</b>	67%	65%	84%
<i>Laggard</i>	<b>82%</b>	69%	81%	73%	45%
Train designated clinicians to train others					
<i>Innovator</i>	21%	17%	<b>22%</b>	14%	7%
<i>Majority</i>	22%	<b>33%</b>	29%	25%	25%
<i>Laggard</i>	9%	6%	<b>19%</b>	13%	9%
Build a local coalition/team to address challenges					
<i>Innovator</i>	53%	<b>65%</b>	30%	33%	13%
<i>Majority</i>	<b>54%</b>	53%	31%	31%	31%
<i>Laggard</i>	45%	38%	<b>75%</b>	7%	27%
Identify and prepare champions					
<i>Innovator</i>	<b>58%</b>	39%	35%	43%	47%
<i>Majority</i>	52%	<b>58%</b>	49%	38%	38%
<i>Laggard</i>	27%	50%	<b>75%</b>	40%	27%
Start with small pilot studies and then scale them up					
<i>Innovator</i>	21%	9%	<b>22%</b>	14%	7%
<i>Majority</i>	24%	<b>26%</b>	23%	19%	9%
<i>Laggard</i>	18%	<b>44%</b>	25%	13%	18%
Conduct small tests of change, measure outcomes, and then refine these tests					
<i>Innovator</i>	<b>21%</b>	13%	13%	14%	7%
<i>Majority</i>	20%	21%	<b>26%</b>	19%	13%
<i>Laggard</i>	9%	31%	<b>50%</b>	20%	9%
Develop and use tools for quality monitoring					
<i>Innovator</i>	<b>42%</b>	17%	30%	14%	7%
<i>Majority</i>	<b>42%</b>	38%	21%	21%	25%
<i>Laggard</i>	36%	31%	<b>56%</b>	33%	0%
Engage in efforts to prepare patients to be active participants in HCV care					
<i>Innovator</i>	<b>84%</b>	52%	57%	38%	33%
<i>Majority</i>	52%	<b>59%</b>	46%	44%	38%
<i>Laggard</i>	<b>73%</b>	56%	56%	47%	27%

1 **Bold** denotes highest use of the strategy per diffusion group

2

3

4